A new study published in The Lancet journal showed that patients with type 2 diabetes and symptomatic peripheral arterial ...

Like in the STRIDE study of PAD, GLP-1s improved outcomes, but more work is needed to clarify who may benefit most.

Ozempic (semaglutide) achieved its main objective with a 13% improvement in maximum walking distance compared to placebo at week 52, translating to an average difference between the groups of ...

Heating the lower limbs before exercise has been found to significantly improve endurance in individuals with heart failure. The study, led by Griffith University, tested the effects of 45 minutes ...

A trial exploring the use of a higher dose of Novo Nordisk's GLP-1 agonist semaglutide has shown that patients with obesity who were taking the drug were able to shed more than a fifth of their ...

Ozempic (semaglutide) helps people with type 2 diabetes lower their blood sugar if diet, exercise, and other diabetes medications haven’t worked. If you’ve just gotten a prescription for it ...

Methods A comprehensive search strategy was conducted to identify relevant studies focused on walking cadence and intensity for adults. Identified studies (n=38) included controlled (n=11), ...

Medical news, education and information for physicians and health care professionals, presented by specialty and topic. From Healio and the Wyanoke Group.